Pharmacokinetics, Safety and Tolerability After Multiple Dose Administration of BI 1467335 in Subjects With Moderate Renal Impairment and Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs BI 1467335 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic retinopathy; Non-alcoholic steatohepatitis; Renal fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Oct 2017 Planned initiation date changed from 17 Oct 2017 to 19 Oct 2017.
- 09 Oct 2017 New trial record